Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Mesp-1 Expression Method to Produce Enriched Cardiovascular Progenitors from Stem Cells
Université Libre de Bruxelles Belgium flag Belgium
Abstract ID:
In the present invention, Mesp1 is identified as the key molecular determinant of multipotent cardiovascular method of differentiation of stem cells into cardiovascular progenitor cells....
Contact Arnaud Quintens
Participants
You
Email me a copy of this message
STATE OF THE ART

The heart is composed by different cell types, including contractile cardiac cells, vascular cells, smooth muscle cells as well as pacemaker cells. During embryonic development as well as during embryonic stem cell (ESC) differentiation, the different cardiovascular cell types arise from the differentiation of multipotent cardiovascular progenitors. The mechanism that promotes multipotent cardiovascular

progenitor specification from undifferentiated mesoderm cell remains largely unknown.

THE INVENTION

In the present invention, Mesp1 is identified as the key molecular determinant of multipotent cardiovascular method of differentiation of stem cells into cardiovascular progenitor cells including the steps of:

• Inducing the expression of Mesp-1 gene in stem cells

• Culturing said induced stem cells in vitro and obtaining differentiated stem cells that are enriched in cardiovascular progenitor cells

• Specifying and differentiating the cardiovascular progenitors generated by method of the invention into a particular subset of cardiovascular lineages such as cardiomyocytes, vascular or endothelial cells.

COMMERCIAL INTEREST

The Mesp-1 expression method can be used to produce high amount of cardiovascular progenitor cells that could be used for transplantation in patient suffering from any condition where cardiac, vascular or conductive cells are lacking.

KEY ADVANTAGES OF THE TECHNOLOGY

• Highly efficient method for generation of cardiovascular cells or progenitors

• Extremely versatile method for promoting cardiac cell differentiation from various sources of stem cells that can be used for:

• cellular therapy in humans but also for,

• tissue engineering & pharmacological and toxicological screening.

GO PREMIUM TO GET PATENT INFORMATION
Type of Business Relationship Sought
license agreement
References
MAIN PUBLICATIONS (related to the patent)
- Defining the earliest step of cardiovascular progenitor specification during embryonic stem cell differentiation. Bondue A, Tännler S, Chiapparo G, Chabab S, Ramialison M, Paulissen C, Beck B, Harvey R, Blanpain C.; J Cell Biol. 2011 Mar 7;192(5):751-65.
- Mesp1 acts as a master regulator of multipotent cardiovascular progenitor specification. Bondue, A., Lapouge, G., Paulissen, C., Semeraro, C., Iacovino, M., Kyba, M. and Blanpain, C. (2008); Cell Stem Cell 3(1):69-84
FEATURED
Last Updated Sep 2014
Technology Type
Phase of Development
UNIVERSITY